UCB announces executive rotation to strengthen growth strategy

Belgian biopharma company UCB (Euronext: UCB) has announced a leadership reshuffle, effective January 1, 2026, as part of a plan to reinforce cross-functional collaboration and sustain growth. The move will see Fiona du Monceau become executive vice president and chief commercial officer, while Emmanuel Caeymaex will transition to head of patient evidence.

Both leaders will begin an immediate handover to ensure operational continuity. Ms du Monceau, who currently oversees product development, regulatory, and medical strategy, brings 25 years of commercial experience to the role. Mr Caeymaex, a 30-year veteran of the company, is credited with helping develop the psoriasis drug Bimzelx (bimekizumab-bkzx).

Chief executive Jean-Christophe Tellier said the decision reflects the company’s focus on agility and innovation. “This strategic rotation is a testament to our belief in dynamic leadership and continuous growth,” he noted. “By leveraging the unique strengths of Fiona and Emmanuel, we are fostering greater collaboration and sparking fresh innovation.”